Industry Daily Summary: What Happened on October 12, 2026

argenx sets a 2030 target for patients and late-stage drugs

argenx acquired Forte Biosciences earlier in 2026 for $2.2 billion.1 CEO Karen Massey said the company aims to treat 50,000 patients across 10 diseases and have five molecules in late-stage development by 2030.1

Massey said three additional treatment formats could reach the market within a few years: a doctor-delivered injection under the skin, a prefilled syringe and an autoinjector.1 She said argenx is also developing an oral FcRn molecule.1

Massey said argenx is developing empasiprubart for multifocal motor neuropathy and chronic inflammatory demyelinating polyneuropathy, and studying it in combination therapy for myasthenia gravis.1 She expects topline results from the Phase 3 multifocal motor neuropathy study in the fourth quarter of 2026.1

Massey said argenx is advancing adimanebart for congenital myasthenic syndromes and other neuromuscular conditions, including spinal muscular atrophy.1 Forte's lead candidate, FB102, is being tested in vitiligo and celiac disease and could address multiple autoimmune conditions, she said.1

Also worth knowing

• 

  Perceptive Discovery and Nucleus RadioPharma formed a non-exclusive partnership connecting preclinical imaging with clinical and commercial manufacturing for radiopharmaceutical programs.2

• M

  Investment funds managed by Neuberger and KKR agreed to acquire a significant minority stake in Datavant. New Mountain Capital will retain control.3

Also published

• Medtech's digital experience is ready for an upgrade pharmaphorum
• Aicuris acquisition delivers new drug for Asahi Kasei pharmaphorum
• Notable TechBio startups and companies operating in Malaysia 🇲🇾 MetaphysicalCells